Therapeutic strategy for IDA should be different among HD patients with high inflammation and those without, and include minimization of a risk of inflammation that increases ferritin and hepcidin-25, leading to hyporesponsiveness to iron therapy. This evidence concerns the gene HAMP and Huntington disease.